Cite

HARVARD Citation

    Lo Re, V. et al. (2017). Postauthorization safety study of the DPP-4 inhibitor saxagliptin: a large-scale multinational family of cohort studies of five outcomes. BMJ open diabetes research and care. 5 (1), p. . [Online]. 
  
Back to record